The von Hippel-Lindau gene: turning discovery into therapy.

The von Hippel-Lindau gene: turning discovery into therapy.
复制标题

DOI:
10.1002/cncr.23645
复制
发表时间:
2008-10-01
期刊:
影响因子:
6.2
通讯作者:
Cookson MS
Cookson MS
中科院分区:
医学1区
文献类型:
--
作者:
Clark PE;Cookson MS

文献摘要

参考文献

被引文献

相似文献

von Hippel-Lindau基因的突变或畸变导致了同名的遗传性肿瘤综合征,以及大多数散发的透明细胞肾细胞癌。该基因的发现和随后对其作用机制的阐明,导致了一系列针对晚期肾癌的靶向治疗,并极大地改变了我们治疗这种疾病的方式。VHL基因的发现是一个很好的例子,说明了实验室的发现如何能够为床边的治疗提供信息和变革。在这篇综述中,作者追溯了这个启发性的故事,从VHL基因的克隆,到阐明其生物学功能,再到新疗法的发展,这些疗法极大地改变了晚期肾细胞癌的治疗模式。
Mutations or aberrations of the von Hippel-Lindau gene are responsible for the hereditary neoplastic syndrome that bears the same name, as well as for the majority of sporadic clear cell renal cell carcinomas. The discovery of this gene and subsequent clarification of its mechanism of action have led to a series of targeted treatments for advanced kidney cancer and have dramatically changed how we manage this disease. The discovery of the VHL gene is a prime example of how discoveries at the bench can inform and revolutionize therapeutics at the bedside. In this review, the authors trace this illuminating tale, from the cloning of the VHL gene, to elucidating its biologic function, to the development of novel therapeutics that have dramatically changed the paradigm of managing advanced renal cell carcinoma.
DOI: 10.1158/1078-0432.ccr-06-1986
发表时间: 2007-01-15
影响因子: 11.5
作者:
Cho, Daniel;Signoretti, Sabina;Atkins, Michael B.
通讯作者: Atkins, Michael B.
DOI: 10.1056/nejm197909133011107
发表时间: 1979-01-01
影响因子: 158.5
作者:
COHEN, AJ;LI, FP;BROWN, RS
通讯作者: BROWN, RS
DOI: 10.1074/jbc.m002740200
发表时间: 2000-08-18
影响因子: 4.8
作者:
Cockman, ME;Masson, N;Maxwell, PH
通讯作者: Maxwell, PH
DOI: 10.1200/jco.2004.08.185
发表时间: 2004-03-01
影响因子: 45.3
作者:
Atkins, MB;Hidalgo, M;Sherman, ML
通讯作者: Sherman, ML
DOI: 10.1136/jmg.33.8.716
发表时间: 1996-08-01
影响因子: 4
作者:
Chen, F;SLife, L;Zbar, B
通讯作者: Zbar, B